These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 7968875)
1. [Bisphosphonate, a new therapy principle in diseases of bone metabolism]. Raue F; Grauer A Med Klin (Munich); 1994 Aug; 89(8):421-8. PubMed ID: 7968875 [No Abstract] [Full Text] [Related]
3. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Toussaint ND; Elder GJ; Kerr PG Clin J Am Soc Nephrol; 2009 Jan; 4(1):221-33. PubMed ID: 18987295 [TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. Cosman F; Borges JL; Curiel MD Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726 [TBL] [Abstract][Full Text] [Related]
5. Is it feasible to adjust bisphosphonate dose according to bone mineral density value in postmenopausal breast cancer patients with bone metastases? Delibasi T; Akkus NI; Altundag O; Pinar T; Altundag K Med Hypotheses; 2006; 66(6):1254-5. PubMed ID: 16413688 [No Abstract] [Full Text] [Related]
6. Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction? Freedman OC; Amir E; Clemons MJ Crit Rev Oncol Hematol; 2009 Oct; 72(1):56-64. PubMed ID: 19307138 [TBL] [Abstract][Full Text] [Related]
7. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Dunstan CR; Felsenberg D; Seibel MJ Nat Clin Pract Oncol; 2007 Jan; 4(1):42-55. PubMed ID: 17183355 [TBL] [Abstract][Full Text] [Related]
8. [Effect of bisphosphonate on myeloma bone disease]. Abe M; Matsumoto T; Kosaka M Rinsho Ketsueki; 2002 May; 43(5):349-52. PubMed ID: 12096484 [No Abstract] [Full Text] [Related]
10. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Magopoulos C; Karakinaris G; Telioudis Z; Vahtsevanos K; Dimitrakopoulos I; Antoniadis K; Delaroudis S Am J Otolaryngol; 2007; 28(3):158-63. PubMed ID: 17499130 [TBL] [Abstract][Full Text] [Related]
11. Management of bisphosphonate treatment in clinical practice. Aapro MS Semin Oncol; 2007 Dec; 34(6 Suppl 4):S28-32. PubMed ID: 18068488 [TBL] [Abstract][Full Text] [Related]
12. Do not use bisphosphonate therapy indefinitely for fracture prevention. Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944 [TBL] [Abstract][Full Text] [Related]
13. Who will benefit from antiresorptive treatment (bisphosphonates)? Papapoulos SE Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):965-73. PubMed ID: 16301190 [TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Doggrell SA Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424 [TBL] [Abstract][Full Text] [Related]
15. [Treating with what? Therapy for how long?]. MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713 [No Abstract] [Full Text] [Related]
16. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Miller PD Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811 [TBL] [Abstract][Full Text] [Related]
18. Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction. Lee S; Glicklich D; Coco M Nephrol Dial Transplant; 2004 Nov; 19(11):2870-3. PubMed ID: 15466880 [TBL] [Abstract][Full Text] [Related]
19. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. Saad F; Sternberg CN Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863 [TBL] [Abstract][Full Text] [Related]
20. [Long-term bisphosphonate administration and its effect on bone metabolism]. Hagino H Clin Calcium; 2005 Apr; 15(4):643-7. PubMed ID: 15802778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]